A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
This study determined the maximum tolerated dose of this combination, demonstrated sustained cPRs in patients with AOGCT, and profiled molecular pharmacodynamic responses that will inform further mechanism-of-action studies. The rate of peripheral neuropathy suggests enhanced tolerability of this combination.
Authors
- Shivaani Kummar (ORCID: https://orcid.org/0000-0001-6906-1627)
- Jennifer Zlott
- Katherine V. Ferry‐Galow
- Mariam M. Konaté (ORCID: https://orcid.org/0000-0003-1708-1348)
- Brandon Miller (ORCID: https://orcid.org/0000-0003-1523-9092)
- Geraldine O’Sullivan Coyne (ORCID: https://orcid.org/0000-0002-2918-6326)
- Deborah Wilsker
- Jerry M. Collins
- Larry Rubinstein (ORCID: https://orcid.org/0000-0002-9720-9737)
- Barry C. Johnson (ORCID: https://orcid.org/0000-0001-9482-2248)
- Murielle Hogu
- James H. Doroshow (ORCID: https://orcid.org/0000-0002-4463-1790)
- Alice P. Chen (ORCID: https://orcid.org/0000-0002-1426-853X)
- Richard Piekarz (ORCID: https://orcid.org/0000-0002-3591-7893)
- Julia Krushkal (ORCID: https://orcid.org/0000-0002-0950-0621)
- Ralph E. Parchment
- Yingdong Zhao (ORCID: https://orcid.org/0000-0002-8514-0293)
- Larry Anderson
- Alida Palmisano (ORCID: https://orcid.org/0000-0002-1859-3719)
- Sarah J. Shin (ORCID: https://orcid.org/0009-0008-8946-5918)
- Lamin Juwara (ORCID: https://orcid.org/0000-0003-1040-655X)
- Sarah B. Miller (ORCID: https://orcid.org/0000-0002-0556-4003)
Institutions
- National Institutes of Health (US)
- Oregon Health & Science University (US)
- Frederick National Laboratory for Cancer Research (US)
- National Cancer Institute (MY)
- National Cancer Institute (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-03-19
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3049
- Citations
- 4
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 6.07